These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 28123293)

  • 1. Inverse relationship between nonadherence to original GOLD treatment guidelines and exacerbations of COPD.
    Foda HD; Brehm A; Goldsteen K; Edelman NH
    Int J Chron Obstruct Pulmon Dis; 2017; 12():209-214. PubMed ID: 28123293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to a COPD treatment guideline among patients in Hong Kong.
    Chan KP; Ko FW; Chan HS; Wong ML; Mok TY; Choo KL; Hui DS
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3371-3379. PubMed ID: 29238182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to GOLD guideline treatment recommendations among pulmonologists in Turkey.
    Sen E; Guclu SZ; Kibar I; Ocal U; Yilmaz V; Celik O; Cimen F; Topcu F; Orhun M; Tereci H; Konya A; Ar I; Saryal S
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2657-63. PubMed ID: 26715844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classifications.
    Ding B; Small M; Holmgren U
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1527-1537. PubMed ID: 28579771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to GOLD guidelines in real-life COPD management in the Puglia region of Italy.
    Palmiotti GA; Lacedonia D; Liotino V; Schino P; Satriano F; Di Napoli PL; Sabato E; Mastrosimone V; Scoditti A; Carone M; Costantino E; Resta E; Attolini E; Foschino Barbaro MP
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2455-2462. PubMed ID: 30147311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiation of triple therapy maintenance treatment among patients with COPD in the US.
    Simeone JC; Luthra R; Kaila S; Pan X; Bhagnani TD; Liu J; Wilcox TK
    Int J Chron Obstruct Pulmon Dis; 2017; 12():73-83. PubMed ID: 28053518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of adherence to the GOLD guidelines on symptom prevalence, lung function decline and exacerbation rate in the Swiss COPD cohort.
    Jochmann A; Scherr A; Jochmann DC; Miedinger D; Török SS; Chhajed PN; Tamm M; Leuppi JD
    Swiss Med Wkly; 2012; 142():w13567. PubMed ID: 22481636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-life data on antibiotic prescription and sputum culture diagnostics in acute exacerbations of COPD in primary care.
    Bathoorn E; Groenhof F; Hendrix R; van der Molen T; Sinha B; Kerstjens HA; Friedrich AW; Kocks JW
    Int J Chron Obstruct Pulmon Dis; 2017; 12():285-290. PubMed ID: 28144133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Categorization of COPD patients in Turkey via GOLD 2013 strategy document: ALPHABET study.
    Gunen H; Yilmaz M; Aktas O; Ergun P; Ortakoylu MG; Demir A; Cetinkaya P; Gurgun A; Otlu M; Cilli A; Yilmaz U; Kokturk N; Candemir I; Yakar HI; Ar I; Konya A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2485-94. PubMed ID: 26622176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guideline for the management of chronic obstructive pulmonary disease--2011 update.
    Abdool-Gaffar MS; Ambaram A; Ainslie GM; Bolliger CT; Feldman C; Geffen L; Irusen EM; Joubert J; Lalloo UG; Mabaso TT; Nyamande K; O'Brien J; Otto W; Raine R; Richards G; Smith C; Stickells D; Venter A; Visser S; Wong M;
    S Afr Med J; 2011 Jan; 101(1 Pt 2):63-73. PubMed ID: 21526617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A score to predict short-term risk of COPD exacerbations (SCOPEX).
    Make BJ; Eriksson G; Calverley PM; Jenkins CR; Postma DS; Peterson S; Östlund O; Anzueto A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():201-9. PubMed ID: 25670896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physicians.
    Salinas GD; Williamson JC; Kalhan R; Thomashow B; Scheckermann JL; Walsh J; Abdolrasulnia M; Foster JA
    Int J Chron Obstruct Pulmon Dis; 2011; 6():171-9. PubMed ID: 21468169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a care pathway for COPD on adherence to guidelines and hospital readmission: a cluster randomized trial.
    Vanhaecht K; Lodewijckx C; Sermeus W; Decramer M; Deneckere S; Leigheb F; Boto P; Kul S; Seys D; Panella M
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2897-2908. PubMed ID: 27920516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants for changing the treatment of COPD: a regression analysis from a clinical audit.
    López-Campos JL; Abad Arranz M; Calero Acuña C; Romero Valero F; Ayerbe García R; Hidalgo Molina A; Aguilar Perez-Grovas RI; García Gil F; Casas Maldonado F; Caballero Ballesteros L; Sánchez Palop M; Pérez-Tejero D; Segado A; Calvo Bonachera J; Hernández Sierra B; Doménech A; Arroyo Varela M; González Vargas F; Cruz Rueda JJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1171-8. PubMed ID: 27330285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting bronchodilator use after hospitalization for COPD: an observational study of health insurance claims data.
    Baker CL; Zou KH; Su J
    Int J Chron Obstruct Pulmon Dis; 2014; 9():431-9. PubMed ID: 24833898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life evaluation of COPD treatment in a Bulgarian population: a 1-year prospective, observational, noninterventional study.
    Ivanov Y; Nikolaev I; Nemeth I
    Int J Chron Obstruct Pulmon Dis; 2018; 13():653-663. PubMed ID: 29503539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.
    Ke X; Marvel J; Yu TC; Wertz D; Geremakis C; Wang L; Stephenson JJ; Mannino DM
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1689-703. PubMed ID: 27555759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013.
    Raluy-Callado M; Lambrelli D; MacLachlan S; Khalid JM
    Int J Chron Obstruct Pulmon Dis; 2015; 10():925-37. PubMed ID: 25999708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease.
    Franssen FM; Spruit MA; Wouters EF
    Int J Chron Obstruct Pulmon Dis; 2011; 6():493-501. PubMed ID: 22069360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.